Ligand Pharmaceuticals (LGND) Assets Average (2011 - 2026)
Ligand Pharmaceuticals (LGND) posted Assets Average of $1.5 billion for Q1 2026, up 1.82% sequentially from $1.5 billion in Q4 2025, and up 67.43% YoY from $923.6 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Assets Average (2011 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $1.5 billion in Q1 2026.
- Quarterly Assets Average rose 67.43% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 67.43% YoY) and the FY2025 annual result came in at $1.3 billion, up 44.73% from the prior year.
- Assets Average rose to $1.5 billion in Q1 2026 per LGND's latest filing, from $1.5 billion in the prior quarter.
- Over five years, Assets Average peaked at $1.5 billion in Q1 2026 and troughed at $763.7 million in Q3 2023.
- A 5-year average of $1.0 billion and a median of $923.6 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2026: Assets Average slumped 34.5% in 2023, then surged 67.43% in 2026.
- Over 5 years, Assets Average stood at $906.6 million in 2022, then fell by 14.16% to $778.2 million in 2023, then increased by 21.86% to $948.3 million in 2024, then jumped by 60.15% to $1.5 billion in 2025, then rose by 1.82% to $1.5 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $1.5 billion, $1.5 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 1.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Bn |
| Mar 31, 2026 | 1.55 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 1.21 Bn |
| Jun 30, 2025 | 927.02 Mn |
| Mar 31, 2025 | 923.60 Mn |
| Dec 31, 2024 | 948.32 Mn |
| Sep 30, 2024 | 910.64 Mn |
| Jun 30, 2024 | 890.14 Mn |
| Mar 31, 2024 | 850.54 Mn |
| Dec 31, 2023 | 778.22 Mn |
| Sep 30, 2023 | 763.67 Mn |
| Jun 30, 2023 | 784.59 Mn |
| Mar 31, 2023 | 786.87 Mn |
| Dec 31, 2022 | 906.64 Mn |
| Sep 30, 2022 | 1.06 Bn |
| Jun 30, 2022 | 1.09 Bn |
| Mar 31, 2022 | 1.20 Bn |
| Dec 31, 2021 | 1.29 Bn |
| Sep 30, 2021 | 1.26 Bn |